The application of Targanta Therapeutics Corp. for oritavancin, a treatment against antibiotic-resistant staphylococcal infections, has been rejected by the FDA because of safety concerns. The agency is also worried that the drug doesn"t work against the most dangerous germs and called for an additional study.